He WL, Yan S, Lu JJ, Chen L, Wu JZ. Current clinical research status and future treatment directions for liver cirrhosis combined with portal vein thrombosis. World J Hepatol 2025; 17(10): 109745 [DOI: 10.4254/wjh.v17.i10.109745]
Corresponding Author of This Article
Jin-Zhu Wu, MD, Chief Physician, Professor, Department of Hepatobiliary Surgery, Nantong Third People’s Hospital, No. 19 Qixiu Road, Chongchuan District, Nantong 226300, Jiangsu Province, China. wjz1258@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Oct 27, 2025 (publication date) through Oct 27, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
He WL, Yan S, Lu JJ, Chen L, Wu JZ. Current clinical research status and future treatment directions for liver cirrhosis combined with portal vein thrombosis. World J Hepatol 2025; 17(10): 109745 [DOI: 10.4254/wjh.v17.i10.109745]
World J Hepatol. Oct 27, 2025; 17(10): 109745 Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.109745
Current clinical research status and future treatment directions for liver cirrhosis combined with portal vein thrombosis
Wen-Long He, Shuai Yan, Jia-Jie Lu, Lin Chen, Jin-Zhu Wu
Wen-Long He, Shuai Yan, Jia-Jie Lu, Jin-Zhu Wu, Department of Hepatobiliary Surgery, Nantong Third People’s Hospital, Nantong 226300, Jiangsu Province, China
Wen-Long He, Shuai Yan, Jia-Jie Lu, Jin-Zhu Wu, Medical School of Nantong University, Nantong 226300, Jiangsu Province, China
Lin Chen, Institute of Liver Diseases, Affiliated Nantong Hospital Three of Nantong University, Nantong 226300, Jiangsu Province, China
Author contributions: He WL and Yan S were responsible for the revision of the manuscript for important intellectual content; Lu JJ and Wu JZ reviewed the literature and contributed to drafting the manuscript; Chen L critically reviewed the manuscript for important intellectual content; and all the authors provided final approval for the version to be submitted for publication.
Supported by the Postgraduate Research and Practice Innovation Program of Jiangsu Province, No. SJCX24_2067; and Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province, No. CXPJJH123009-079.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jin-Zhu Wu, MD, Chief Physician, Professor, Department of Hepatobiliary Surgery, Nantong Third People’s Hospital, No. 19 Qixiu Road, Chongchuan District, Nantong 226300, Jiangsu Province, China. wjz1258@163.com
Received: May 20, 2025 Revised: June 4, 2025 Accepted: September 22, 2025 Published online: October 27, 2025 Processing time: 160 Days and 8 Hours
Core Tip
Core Tip: Portal vein thrombosis represents a significant complication of liver cirrhosis and contributes to the exacerbation of portal hypertension and results in severe clinical outcomes including oesophageal variceal bleeding and refractory ascites. This review presents a comprehensive overview of the aetiology, diagnosis, clinical manifestations, and treatment options for portal vein thrombosis in cirrhotic patients. Furthermore, this highlights the emerging role of direct oral anticoagulants, such as edoxaban, which offer promising therapeutic potential because of their efficacy, safety, and convenience. Future research should address individualized treatment strategies to optimize the balance between anticoagulation benefits and bleeding risks, which improves patient prognosis.
